Navigating the Next Frontier of Precision Oncology: Breakthroughs in VEGFR2-Targeted ADCs and Novel Payloads
As we progress through the first quarter of 2026, the landscape of targeted cancer therapy is undergoing a significant transformation. Among the most promising modalities, Antibody-Drug Conjugates (ADCs) continue to dominate the discussion, particularly with the emergence of high-affinity antibodies targeting the vascular endothelial growth factor receptor 2 (VEGFR2) and the integration of...
0 Bình luận
0 Chia sẻ
86 Lượt xem
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)